Practical Perspectives on Acute Lymphocytic Leukemia

Practical Perspectives on Acute Lymphocytic Leukemia

Episodes

Specialty:

All

Year:

All

EP. 1: Acute Lymphoblastic Leukemia: Risk Stratification

January 29th 2018

EP. 2: T-Cell Acute Lymphoblastic Leukemia: Impacting Prognosis

January 29th 2018

EP. 3: Philadelphia Chromosome-Positive ALL: Upfront Approaches

January 29th 2018

EP. 4: Defining Ponatinib's Role in Ph-Positive ALL

January 29th 2018

EP. 5: Up-front Approaches to Treating Ph-Negative ALL

January 29th 2018

EP. 6: Optimizing Allogeneic Transplant Strategies in ALL

January 29th 2018

EP. 7: Importance of MRD Testing in Acute Lymphoblastic Leukemia

January 29th 2018

EP. 8: MRD Testing in ALL: Sensitivity and Availability

January 29th 2018

EP. 9: Acute Lymphoblastic Leukemia: Challenges in MRD Testing

January 29th 2018

EP. 10: Acute Lymphoblastic Leukemia: Optimizing MRD Testing

January 29th 2018

EP. 11: ALL: Therapy for Post-Induction MRD-Positivity

January 29th 2018

EP. 12: MRD-Positive ALL: Personal Approaches to Treatment

January 29th 2018

EP. 13: Approaching Treatment for Relapsed/Refractory ALL

January 29th 2018

EP. 14: Relapsed/Refractory ALL: Evaluating Novel Agents

January 29th 2018

EP. 15: Relapsed/Refractory ALL: Inotuzumab Ozogamicin

January 29th 2018

EP. 16: Role of CAR T-Cell Therapy in Relapsed/Refractory ALL

January 29th 2018

EP. 17: Acute Lymphoblastic Leukemia: The Future of Treatment

January 29th 2018

Trending on OncLive

Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC

Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL

Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC

Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings

Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC